Inherited Retinal Disease Market Report 2026

The inherited retinal disease market size has grown strongly in recent years. It will grow from $12.54 billion in 2025 to $13.6 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to identification of disease-causing retinal genes, advancements in retinal imaging technologies, increased awareness of inherited eye disorders, growth of specialized ophthalmology clinics, public and private funding for rare disease research.

The inherited retinal disease market size is expected to see strong growth in the next few years. It will grow to $18.62 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to advancements in gene therapy platforms, rising approvals of novel retinal therapies, increasing availability of genetic screening programs, expansion of precision medicine initiatives, growing investment in rare ophthalmic disease pipelines. Major trends in the forecast period include increasing adoption of genetic testing for early diagnosis, growing focus on gene and cell-based therapies, expansion of personalized treatment approaches, rising clinical trials for rare retinal disorders, improved patient access to advanced retinal imaging.

The rising prevalence of macular degeneration is expected to drive the growth of the inherited retinal disease market in the coming years. Macular degeneration is an age-related eye disorder that damages the macula, leading to central vision loss and difficulties in activities such as reading or recognizing faces. Factors contributing to the increasing prevalence include aging populations, higher life expectancy, and lifestyle factors such as smoking and poor nutrition. Treatments for inherited retinal diseases assist macular degeneration patients by targeting the underlying genetic causes of retinal degeneration, offering therapies that slow disease progression, restore lost vision, or prevent further retinal damage, ultimately improving visual outcomes and quality of life. For example, in February 2024, the Canadian Ophthalmological Society, a Canada-based nonprofit organization, reported that 2.5 million Canadians aged over 55 experience vision loss due to age-related macular degeneration (AMD). Therefore, the growing prevalence of macular degeneration is boosting the inherited retinal disease market.

Leading companies in the inherited retinal disease market are developing innovative therapies, such as mutation-agnostic gene therapy, to provide inclusive treatment options and address a broader spectrum of genetic variations. Mutation-agnostic gene therapy targets general genetic mechanisms or pathways rather than specific mutations, making it suitable for a range of genetic disorders. For instance, in March 2024, Nanoscope Therapeutics Inc., a US-based biotechnology company, announced positive clinical trial results for its lead program, MCO-010, demonstrating vision improvements in patients with permanent and severe vision loss from advanced retinitis pigmentosa. The program achieved its primary and key secondary endpoints with statistical significance and no serious adverse events.

In October 2024, Ocuphire Pharma, Inc., a US-based biopharmaceutical company, acquired Opus Genetics Inc. for an undisclosed amount. This acquisition enables Ocuphire Pharma to strengthen its gene therapy portfolio and accelerate the development of innovative treatments for inherited retinal diseases (IRDs) by integrating Opus Genetics’ advanced gene therapies targeting rare retinal conditions. Opus Genetics Inc. is a US-based clinical-stage gene therapy company focused on inherited retinal diseases.

Major companies operating in the inherited retinal disease market are Johnson & Johnson, Novartis AG, Astellas Pharma Inc., Biogen Inc., Ionis Pharmaceuticals Inc., Invitae Corporation, Spark Therapeutics, Aldeyra Therapeutics, Regenxbio Inc., IVERIC bio, MeiraGTx Limited, Ocugen Inc., Coave Therapeutics, Bionic Vision Technologies, GenSight Biologics SA, LKC Technologies Inc., Sparing Vision, ProQR Therapeutics NV, Endogena Therapeutics.

North America was the largest region in the inherited retinal disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inherited retinal disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the inherited retinal disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the inherited retinal disease market by increasing costs of genetic testing kits, advanced imaging equipment, and gene therapy manufacturing inputs sourced internationally. These effects are most pronounced in diagnostic and therapy segments, particularly across north america, europe, and asia-pacific regions that rely on cross-border biotechnology supply chains. Higher tariffs have raised treatment and diagnostic costs for hospitals and specialty clinics. However, tariffs are also encouraging domestic production of diagnostic tools, local biomanufacturing investments, and regional clinical research capabilities, supporting long-term market resilience.

The inherited retinal disease market research report is one of a series of new reports that provides inherited retinal disease market statistics, including inherited retinal disease industry global market size, regional shares, competitors with a inherited retinal disease market share, detailed inherited retinal disease market segments, market trends and opportunities, and any further data you may need to thrive in the inherited retinal disease industry. This inherited retinal disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Inherited retinal diseases (IRDs) are a group of rare, genetic eye disorders caused by mutations in specific genes. These conditions primarily affect the retina, the thin layer of light-sensitive tissue at the back of the eye. Due to their genetic complexity, IRDs often present challenges in treatment; however, advances in gene therapy and other innovative technologies are providing promising solutions.

The main types of treatment for inherited retinal diseases include diagnosis and therapy. Diagnostic approaches utilize advanced technologies such as genetic testing, optical coherence tomography, and fundus imaging to identify IRDs and their underlying genetic causes. These treatments target various conditions, including retinitis pigmentosa, choroideremia, Stargardt disease, cone-rod dystrophy, Leber congenital amaurosis, and others. Diagnostic and therapeutic solutions are distributed through channels such as retail sales and direct tender, and are used by hospitals, specialty clinics, ambulatory surgical centers, home healthcare providers, and other end users.

The inherited retinal disease market includes revenues earned by entities by providing services such as ophthalmic tests, optic nerve imaging, and electrophysiological tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.